Hormonal
GLP-1 receptor agonists (GLP-1 RAs) promote significant, sustained weight loss in adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with comorbidities, primarily through central nervous system-mediated appetite suppression and reduced caloric intake, with efficacy superior to previously approved anti-obesity medications.
GLP-1 agonists like semaglutide and liraglutide are FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities. They work by targeting hormonal pathways in the brain to reduce hunger and increase satiety, leading to significant, sustained weight loss that is roughly double that of older medications. Treatment is available in daily or weekly injectable forms, as well as oral tablets, and is intended for long-term use to maintain results without the 'Yo-Yo' effect common with short-term diets.
GLP-1 RAs are currently used in treating patients with T2D and consistently result in weight loss... The combined central and peripheral actions of GLP-1 RA promote satiety, decrease hunger, and ultimately reduce food intake... Compared to the data for previously approved obesity medications, the phase 3 randomized controlled trial data for this treatment showed nearly twice the weight loss.
Why this rating
The paper is a comprehensive review of Randomised Controlled Trials (RCTs) and FDA approvals, citing high-quality clinical data.
Source
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu et al. · International Journal of Molecular Sciences · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →